Abstract
We conducted a cohort study of acute, noninfectious liver injury among oral antimicrobial users. Potential cases were identified in the HealthCore Integrated Research Database (HIRDSM) population between July 1, 2001, and March 31, 2009, using ICD-9-CM codes primarily for acute and subacute necrosis of the liver, hepatic coma, and unspecified hepatitis.
Liver test results were used to confirm case status according to published criteria. Two physician reviewers experienced in studying acute liver injury (blinded to study drug exposures) evaluated data abstracted from hospital and emergency department records to validate potential cases. Of 715 potential cases having claims associated with any of the primary screening codes, 312 (44%) were valid cases, 108 (15%) were not cases, and 295 (41%) were of uncertain status (records inadequate for validation). Among potential cases with adequate medical records, the PPV for presence of any of the primary codes was 74% (95% CI, 70%-78%). The highest PPV for a single code was for acute and subacute necrosis of the liver (84%; 95% CI, 77%-90%).
Evaluation of cases of noninfectious liver injury using hospital and emergency department medical records continues to represent the preferred approach in studies using insurance claims data.
Keywords: Antimicrobials, cohort, liver injury, nested case-control, validation.
Current Drug Safety
Title:Validation of Acute Liver Injury Cases in a Population-Based Cohort Study of Oral Antimicrobial Users
Volume: 9 Issue: 1
Author(s): Christine L. Bui, James A. Kaye, Jordi Castellsague, Brian Calingaert, Lisa J. McQuay, Nuria Riera-Guardia, Catherine W. Saltus, Scott C. Quinlan, Crystal N. Holick, Peter M. Wahl, Kiliana Suzart, Kenneth J. Rothman, Mari-Ann Wallander and Susana Perez-Gutthann
Affiliation:
Keywords: Antimicrobials, cohort, liver injury, nested case-control, validation.
Abstract: We conducted a cohort study of acute, noninfectious liver injury among oral antimicrobial users. Potential cases were identified in the HealthCore Integrated Research Database (HIRDSM) population between July 1, 2001, and March 31, 2009, using ICD-9-CM codes primarily for acute and subacute necrosis of the liver, hepatic coma, and unspecified hepatitis.
Liver test results were used to confirm case status according to published criteria. Two physician reviewers experienced in studying acute liver injury (blinded to study drug exposures) evaluated data abstracted from hospital and emergency department records to validate potential cases. Of 715 potential cases having claims associated with any of the primary screening codes, 312 (44%) were valid cases, 108 (15%) were not cases, and 295 (41%) were of uncertain status (records inadequate for validation). Among potential cases with adequate medical records, the PPV for presence of any of the primary codes was 74% (95% CI, 70%-78%). The highest PPV for a single code was for acute and subacute necrosis of the liver (84%; 95% CI, 77%-90%).
Evaluation of cases of noninfectious liver injury using hospital and emergency department medical records continues to represent the preferred approach in studies using insurance claims data.
Export Options
About this article
Cite this article as:
Bui L. Christine, Kaye A. James, Castellsague Jordi, Calingaert Brian, McQuay J. Lisa, Riera-Guardia Nuria, Saltus W. Catherine, Quinlan C. Scott, Holick N. Crystal, Wahl M. Peter, Suzart Kiliana, Rothman J. Kenneth, Wallander Mari-Ann and Perez-Gutthann Susana, Validation of Acute Liver Injury Cases in a Population-Based Cohort Study of Oral Antimicrobial Users, Current Drug Safety 2014; 9 (1) . https://dx.doi.org/10.2174/15748863113086660051
DOI https://dx.doi.org/10.2174/15748863113086660051 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Economic Costs for the Control of Cardiovascular Risk: An Overview
Current Pharmaceutical Design Recent Advances and Approaches in Targeting Apoptosis Signaling Pathways for Anti-Cancer Therapeutics
Current Cancer Therapy Reviews Generation of Mesenchymal Stem Cells by Blood Cell Reprogramming
Current Stem Cell Research & Therapy Irreversible Inhibition of Serine Proteases – Design and In Vivo Activity of Diaryl α-Aminophosphonate Derivatives
Current Medicinal Chemistry Essential Roles of Intracellular Calcium Release Channels in Muscle, Brain, Metabolism, and Aging
Current Molecular Pharmacology Ignored Avenues in Alpha-Synuclein Associated Proteopathy
CNS & Neurological Disorders - Drug Targets Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Antagonists in Experimental Myocarditis
Current Pharmaceutical Design Toll Like Receptors Signaling Pathways as a Target for Therapeutic Interventions
Current Signal Transduction Therapy Design, Synthesis, and Structure-Activity Relationship Study of Peroxisome Proliferator-Activated Receptor (PPAR) δ-Selective Ligands
Current Medicinal Chemistry Tumor Necrosis Factor Inhibitors from Poxviruses with An Emphasis on Tanapoxvirus-2L Protein
Recent Patents on DNA & Gene Sequences Nanomedicines as Cancer Therapeutics: Current Status
Current Cancer Drug Targets Chemokines and Chemokine Receptors Blockers as New Drugs for the Treatment of Chronic Obstructive Pulmonary Disease
Current Medicinal Chemistry G Protein-Coupled Receptor Fusion Proteins in Drug Discovery
Current Pharmaceutical Design iTRAQ-Based Quantitative Proteomic Analysis of <i>Pseudostellaria heterophylla</i> from Geo-Authentic Habitat and Cultivated Bases
Current Proteomics Targeting Cancer Stem Cells with Repurposed Drugs to Improve Current Therapies
Recent Patents on Anti-Cancer Drug Discovery SAR, QSAR and Docking of Anticancer Flavonoids and Variants: A Review
Current Topics in Medicinal Chemistry Leptin and Vascular Smooth Muscle
Current Vascular Pharmacology Pharmacological Effects of RAAS Blockade in Ischemic Nephropathy
Current Drug Metabolism Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Assessment of Response to Treatment and Follow-Up in Gastroenteropancreatic Neuroendocrine Neoplasms
Endocrine, Metabolic & Immune Disorders - Drug Targets Propofol: Therapeutic Indications and Side-Effects
Current Pharmaceutical Design